GlassScriptPhysician profile
Amanda S Davis-Houchen
NPI 1538396155
$4,629.12
in general payments reported to CMS, 2019-2025
27 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,162 · 2022: $1,345 · 2023: $1,005 · 2024: $909 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $555.54 | 2021-2024 | Trelegy Ellipta |
| Gilead Sciences, INC. | $501.46 | 2021-2024 | Descovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.81 | 2021-2025 | Caplyta |
| Lundbeck LLC | $192.58 | 2022-2024 | Rexulti, Abilify Maintena |
| Indivior INC. | $168.15 | 2022-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $151.30 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $143.09 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Exact Sciences Corporation | $134.11 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $126.94 | 2021-2025 | Farxiga, Breztri |
| Alkermes, INC. | $115.54 | 2021-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $111.47 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $89.43 | 2022-2024 | Invega Sustenna |
| Merck Sharp & Dohme LLC | $71.29 | 2021-2025 | Pifeltro, Gardasil 9, Vaxelis |
| Novo Nordisk INC | $65.10 | 2021-2025 | Rybelsus, Ozempic |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.93 | 2021-2023 | Mounjaro, Trulicity |
| Idorsia Pharmaceuticals US INC | $54.17 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $50.99 | 2022-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $40.88 | 2023-2024 | Auvelity |
| Pfizer INC. | $35.68 | 2023 | |
| Verona Pharma, INC. | $34.20 | 2025 | Ohtuvayre |
| Eisai INC. | $32.02 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $20.30 | 2024 | Uzedy |
| Impel Pharmaceuticals INC. | $14.95 | 2022 | |
| Amgen INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Davis-Houchen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.